Absence of copy number gain of EGFR: A possible predictive marker of long‐term response to afatinib
Absence of copy number gain of EGFR: A possible predictive marker of long‐term response to afatinib
About this item
Full title
Author / Creator
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Treatment efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) is diverse even in non‐small cell lung cancer (NSCLC) patients with EGFR activating mutations. Extraordinary long‐term responses sustained over 3 years among NSCLC patients treated with afatinib, an EGFR‐TKI, have been reported, but how to predict such long...
Alternative Titles
Full title
Absence of copy number gain of EGFR: A possible predictive marker of long‐term response to afatinib
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9986088
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9986088
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/cas.15655
